Market Cap 348.75M
Revenue (ttm) 70.84M
Net Income (ttm) -157.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -222.83%
Debt to Equity Ratio -0.57
Volume 1,182,600
Avg Vol 790,068
Day's Range N/A - N/A
Shares Out 112.50M
Stochastic %K 90%
Beta 1.92
Analysts Strong Sell
Price Target $8.20

Company Profile

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 21 653 02 00
Address:
BiopOle, Route de la Corniche 3B, Epalinges, Switzerland
belugatrade
belugatrade Aug. 22 at 6:50 PM
$ADCT beauty!
0 · Reply
JRobb66
JRobb66 Aug. 22 at 8:34 AM
$ADCT what is the story here?? Nothing but good news and it falls below $3? C’mon now.. it’s a $10 stock all day..
0 · Reply
fort_worth_Jason
fort_worth_Jason Aug. 19 at 7:01 PM
$ADCT- nothing but good news last week.
0 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 1:47 PM
Guggenheim has adjusted their stance on ADC Therapeutics ( $ADCT ), setting the rating to Buy with a target price of 10.
0 · Reply
d_risk
d_risk Aug. 13 at 5:41 AM
$ADCT - ADC Therapeutics SA Common Shares - 10Q - Updated Risk Factors ADCT flags new risks from potential tariff hikes raising costs and possible U.S. drug pricing policy shifts threatening product sales revenue. #Biotechnology #RegulatoryRisk #DrugPricing #TariffRisks #Pharmaceuticals 🟢 Added 🟠 Removed https://d-risk.ai/ADCT/10-Q/2025-08-12
0 · Reply
SirBensonNaija
SirBensonNaija Aug. 13 at 1:56 AM
$ADCT long
0 · Reply
JRobb66
JRobb66 Aug. 12 at 2:29 PM
$ADCT a whole lot of nothing So strange…
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 12 at 11:38 AM
$ADCT ADC Therapeutics Q2 Adj. EPS $(0.25) Beats $(0.39) Estimate, Sales $18.839M Beat $17.776M Estimate
1 · Reply
Dumont77
Dumont77 Aug. 11 at 4:07 PM
I like $ADCT as high risk play.
0 · Reply
christopher18
christopher18 Aug. 8 at 4:48 PM
$ADCT Predictions on Tuesday!
2 · Reply
Latest News on ADCT
ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 11:27 AM EDT - 10 days ago

ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript


ADC Therapeutics to Present at Upcoming Investor Conferences

May 15, 2025, 7:15 AM EDT - 3 months ago

ADC Therapeutics to Present at Upcoming Investor Conferences


ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:36 PM EDT - 3 months ago

ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript


ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 11:17 AM EDT - 5 months ago

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript


ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 11:01 AM EST - 10 months ago

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript


ADC Therapeutics to Present at November Investor Conferences

Nov 4, 2024, 7:15 AM EST - 10 months ago

ADC Therapeutics to Present at November Investor Conferences


ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 9:26 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q2 2024 Earnings Call Transcript


ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript

May 6, 2024, 11:04 AM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript


ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 1:24 PM EDT - 1 year ago

ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript


belugatrade
belugatrade Aug. 22 at 6:50 PM
$ADCT beauty!
0 · Reply
JRobb66
JRobb66 Aug. 22 at 8:34 AM
$ADCT what is the story here?? Nothing but good news and it falls below $3? C’mon now.. it’s a $10 stock all day..
0 · Reply
fort_worth_Jason
fort_worth_Jason Aug. 19 at 7:01 PM
$ADCT- nothing but good news last week.
0 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 1:47 PM
Guggenheim has adjusted their stance on ADC Therapeutics ( $ADCT ), setting the rating to Buy with a target price of 10.
0 · Reply
d_risk
d_risk Aug. 13 at 5:41 AM
$ADCT - ADC Therapeutics SA Common Shares - 10Q - Updated Risk Factors ADCT flags new risks from potential tariff hikes raising costs and possible U.S. drug pricing policy shifts threatening product sales revenue. #Biotechnology #RegulatoryRisk #DrugPricing #TariffRisks #Pharmaceuticals 🟢 Added 🟠 Removed https://d-risk.ai/ADCT/10-Q/2025-08-12
0 · Reply
SirBensonNaija
SirBensonNaija Aug. 13 at 1:56 AM
$ADCT long
0 · Reply
JRobb66
JRobb66 Aug. 12 at 2:29 PM
$ADCT a whole lot of nothing So strange…
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 12 at 11:38 AM
$ADCT ADC Therapeutics Q2 Adj. EPS $(0.25) Beats $(0.39) Estimate, Sales $18.839M Beat $17.776M Estimate
1 · Reply
Dumont77
Dumont77 Aug. 11 at 4:07 PM
I like $ADCT as high risk play.
0 · Reply
christopher18
christopher18 Aug. 8 at 4:48 PM
$ADCT Predictions on Tuesday!
2 · Reply
hechicero1131
hechicero1131 Jul. 30 at 7:28 PM
$ADCT This sucks, huge green candles offset by major price drops on <5000 shares
0 · Reply
JRobb66
JRobb66 Jul. 29 at 2:57 PM
$ADCT maybe somebody knows something… too big of a sloooow drop
1 · Reply
fort_worth_Jason
fort_worth_Jason Jul. 24 at 4:41 PM
$ADCT Hoping for some good news soon.
0 · Reply
vjtweet
vjtweet Jul. 23 at 3:19 PM
$ADCT starter position.. to add more above 3.3
0 · Reply
JRobb66
JRobb66 Jul. 23 at 8:48 AM
$ADCT FFS under $3?
0 · Reply
SwingGio
SwingGio Jul. 22 at 8:35 AM
$ADCT price compressing
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 20 at 7:26 PM
The attachment shows commercial-stage oncology focused bio shares trade @ meaningfully lower FY28 revenue multiples than non-oncology. Share prices are also lower YTD (as a peer group). We're merely sharing an observation. We're not suggesting oncology will catch up or otherwise fare batter in the future. The attachment shows all 37 comm'l-stage oncology focused bios (including 2 with PDUFAs) versus all 37 like non-oncology with market caps over $1.5B and all 37 with market caps of $160MM to $1.5B In the Tesaro fair value opinion (when acquired by GSK in 1/2019), Centerview Partners noted that oncology focused bios get roughly 8% better Year 3 multiples in M&A. Yes that was 6 years ago. We'd genuinely like to know if anyone can offer an explanation as to why oncology trades at lower FY2028 multiples than their non-oncology focused peers? $JAZZ $NVCR $SNDX $IOVA $ADCT
7 · Reply
SamHot
SamHot Jul. 16 at 7:18 PM
0 · Reply
SamHot
SamHot Jul. 16 at 7:15 PM
$ADCT Buy n Buy
0 · Reply
SamHot
SamHot Jul. 16 at 7:11 PM
$ADCT Time to buy more
0 · Reply
SamHot
SamHot Jul. 16 at 7:10 PM
0 · Reply
FavoredTrades
FavoredTrades Jul. 9 at 6:07 PM
$ADCT like this for weeks to come
0 · Reply